Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, James N. Kochenderfer, Jesús G. Berdeja et al.|New England Journal of Medicine|2019Cited by 1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 MutationsDavid M. Hyman, José Baselga, Igor Puzanov et al.|New England Journal of Medicine|2015Cited by 1.7k
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaFaith E. Davies, Kenneth C. Anderson, Noopur Raje et al.|Blood|2001Cited by 905
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disordersJens Hillengaß, Suzanne Lentzsch, Elena Zamagni et al.|The Lancet Oncology|2019Cited by 493
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G. Richardson, Irene M. Ghobrial, Susanna Jacobus et al.|New England Journal of Medicine|2022Cited by 457